Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
  • A61K33/08—Oxides; Hydroxides
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/16—Inorganic salts, minerals or trace elements
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/76—Salicaceae (Willow family), e.g. poplar
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates to the association of feverfew dry extract, willow dry extract and magnesium for use as an adjuvant in the prophylaxis and treatment of migraine and related oral compositions, in particular as a food supplement.
• headaches have been re-catalogued according to different diagnostic levels, since it is important for the general practitioner to know at least the first and the second diagnostic levels of the classification.
• migraine without aura migraine without aura
• migraine with aura childhood episodic syndromes that are possible migraine precursors, such as cyclic vomiting and abdominal migraine, paroxysmal vertigo; chronic migraine, cluster headache and tension headache.
• Migraine with and without aura is a very common primary headache in Italy that has a high prevalence and a significant socio-economic impact in today's society.
• Migraine without aura generally begins in adolescence or in early adulthood, but can also arise in childhood. However, an onset at 40-50 years of age is unlikely. It is a recurrent headache, in which a familiarity is often frequent.
• migraine sufferers tend to stay in bed, preferably in the dark and instinctively try to compress and cool the painful part.
• the factors that most often trigger migraine without aura are psychological factors, routine changes, dietary factors, environmental factors, chemicals, work environment and hormonal factors.
• Migraine with aura affects about 3-5% of the general population with a female-male ratio of 2: 1. In almost 90% of cases, it begins within the age of 30.
• the distinctive element is the aura that generally precedes the headache and consists of a series of neurological symptoms due to focal encephalic dysfunction. These are visual, sensory, motor, retinal symptoms, alteration of speech and language and symptoms of encephalic brain dysfunction.
• Chronic migraine is due to a chronification of migraine without aura.
• Cluster headache takes its name from the particular mode of recurrence of the attacks, which are grouped in delimited time periods. This type of headache affects 2-3 people in a thousand and, contrary to the previous ones, affects the male population more than the female.
• a distinctive feature is the behaviour of the patient during the acute phase. Contrary to the migraine, the patient affected by cluster headache does not remain in a fixed position, is in continuous movement and is agitated and irritable.
• migraine is triggered by a complex neurobiological phenomenon, caused by transient alterations of the functionality of nerve cells with no gross alterations of the nervous system.
• the neurophysiological bases of migraine are scarcely known today.
• neurotransmitters such as serotonin and neuronal membrane proteins are involved, such as the so-called sodium and potassium pump and other ion channels of the cell membrane.
• irritability, anxiety states and depressive states contribute to their chronification.
• migraine also involves a disturbance of the functionality of the vascular endothelium.
• the succession of migraine attacks with the consequent repetition of vasodilatative and oxidative phenomena can damage the endothelium functionality, thus causing an increase in its ability to produce vasoconstrictive substances at the expense of vasodilators.
• a migraine treatment should act on various factors, such as rebalancing the levels of serotonin, reducing oxidative inflammatory stress and stabilizing the cerebral electrical system.
• the first and the most used for this type of pathology is the so-called feverfew, because it reduces the vasodilatation of the arterioles, favours the nociceptive reduction of the trigeminal and reduces the main cerebral proinflammatory cytokines (IL6, TNF-a, NF-kB) (2> 3> 4> 5) .
• the white willow dry extract (Salix alba) shows a general anti-inflammatory action, typical of salicylic derivatives.
• this phytocomplex is used as antineuralgic and antipyretic drug, useful in case of rheumatism, joint and muscle pain, back pain, neuralgia, excellent against headaches (2 ' 6 ' 7 ' 8) .
• a good medicament for migraine treatment and prophylaxis also needs to exert a greater control over the causes of migraine, which can for example be cerebral stress and anxiety states.
• Magnesium has a muscle relaxant and anxiolytic activity. The lack of this mineral causes neuronal hyper excitability, thus playing an important role in the pathogenesis of the migraine attack. Indeed, it has been shown that the serum and intracellular magnesium levels are significantly reduced in subjects with migraine, ( ' ⁇ .
• magnesium sulphate corresponding to about 200 mg of magnesium
• intravenously administered intravenously have shown a statistical improvement of all symptoms of migraine with aura or as an adjuvant in the treatment of migraine without aura.
• the same amount of intravenous magnesium sulphate administered as a fast-acting drug is as effective as an association of dexamethasone and metoclopramide for the treatment of acute migraine (10 ' U) .
• a further clinical study shows that intravenously administered magnesium sulphate in the same amounts of the previous studies is as effective as an intravenously administered NSAID such as ketorolac (12) .
• a further object of the present invention is an oral composition comprising the aforesaid association together with suitable excipients and/or diluents.
• a further object of the present invention is a supplement comprising or even better consisting of the aforesaid oral composition.
• the expression “comprising/containing one or more components” does not exclude the presence of further components besides the one or more explicitly listed.
• the expression in which an object "is made up or formed or composed of one or more components” means that the presence of further components in the object besides the one or more listed components is excluded.
• the above-mentioned association for use according to the present invention is orally administered.
• the dry extract of feverfew in the association for use according to the present invention is preferably from the blossomed aerial parts of this plant and preferably has a parthenolide titration of at least 0.5%, and not more than 10%.
• the dry extract of white willow comes preferably from the cortex of this plant and has a content in salicylic derivatives, and in particular in salicin, characterized by the following formula:
• the amount of the dose of white willow extract to be administered for use according to the present invention must not exceed the maximum daily dose of salicin of 96 mg, as per Ministerial Regulations for Food Supplements.
• oxide or a pharmaceutically acceptable salt is used as the source of magnesium.
• Magnesium oxide is even more preferably used. Magnesium oxide, in fact, makes up 60% of the total weight of this compound, unlike pharmaceutically acceptable magnesium salts such as magnesium carbonate or citrate, containing only 24% and 14% of this element.
• the oral compositions object of the present invention can be in the form of tablets, hard or soft capsules, powders or granules in the form of single-serving sachets, dispersible in water.
• feverfew with the aforesaid titration in amounts preferably ranging from 100 to 170 mg, more preferably 140 mg,
• ⁇ magnesium in amounts ranging from 200 to 250 mg, more preferably 225 mg.
• the food supplement consists of said tablets, which are administered twice a day.
• the daily salicin amount must not exceed the aforementioned maximum permitted amount of 96 mg, and must not exceed the maximum permitted daily amount of magnesium of 450 mg, as per Ministerial Regulations for Food Supplements.
• food or dietary supplements correspond to the definition given in Article 2 of the Legislative Decree No. 169 of 21 May 2004, i.e. food products intended to supplement the common diet and constituting a concentrated source of nutrients, such as vitamins and minerals, or of other substances having a nutritional or physiological effect, in particular, but not exclusively, amino acids, essential fatty acids, fibres and extracts of plant origin, alone or in combination, in pre-dosed forms.
• composition for food supplement in the form of tablets, in which the excipients and their contents are not reported.
• excipients involved in the preparation of this particularly preferred embodiment of food supplement according to the present invention are conventional excipients for the preparation of compressible powders, for example those mentioned in Remington the Science and Practice of Pharmacy 21st Edition.
• EXAMPLE 1 Food supplement formula for 1.2 g tablets administrable twice a day.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Mycology (AREA)
• Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Botany (AREA)
• Inorganic Chemistry (AREA)
• Medical Informatics (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Alternative & Traditional Medicine (AREA)
• Molecular Biology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Plant Substances (AREA)
• Medicinal Preparation (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (10)

Applications Claiming Priority (2)

Publications (1)

Family

ID=60451071

Family Applications (1)

Country Status (12)

Families Citing this family (2)

Citations (6)

Family Cites Families (4)

• 2017
  • 2017-07-26 IT IT102017000085185A patent/IT201700085185A1/it unknown
• 2018
  • 2018-07-23 PL PL18753247.8T patent/PL3657964T3/pl unknown
  • 2018-07-23 CA CA3069285A patent/CA3069285A1/en active Pending
  • 2018-07-23 CN CN202410371868.6A patent/CN118203111A/zh active Pending
  • 2018-07-23 CN CN201880048234.XA patent/CN111031814A/zh active Pending
  • 2018-07-23 ES ES18753247T patent/ES2917975T3/es active Active
  • 2018-07-23 PT PT187532478T patent/PT3657964T/pt unknown
  • 2018-07-23 DK DK18753247.8T patent/DK3657964T3/da active
  • 2018-07-23 JP JP2020526709A patent/JP2020528462A/ja not_active Withdrawn
  • 2018-07-23 US US16/633,280 patent/US11458160B2/en active Active
  • 2018-07-23 WO PCT/IB2018/055454 patent/WO2019021148A1/en not_active Ceased
  • 2018-07-23 EP EP18753247.8A patent/EP3657964B1/en active Active
  • 2018-07-23 HU HUE18753247A patent/HUE059251T2/hu unknown
• 2024
  • 2024-02-22 JP JP2024025829A patent/JP2024061731A/ja active Pending

Patent Citations (6)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events